Cybin (OTCMKTS:CYBN) had its "buy" rating reaffirmed by analysts at Guggenheim.
Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges [Yahoo! Finance]
Cybin (OTCMKTS:CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $70.00 to $45.00. They now have a "buy" rating on the stock.
Cybin (OTCMKTS:CYBN) had its price target lowered by analysts at HC Wainwright from $150.00 to $55.00. They now have a "buy" rating on the stock.
Fibroblast Growth Factors Market Global Forecast Report 2025-2030: Opportunities in Regenerative Medicine, Oncology, and Metabolic Disorders Due to Advances in Molecular Biology, Delivery Technologies [Yahoo! Finance]